NVCRNovoCure Limited
$14.66+4.5% 1Y
$14.66
$10.0352 weeks$20.00
Latest close: below its 200-day averageOct 23, 2026what changed →
Is the price fair?
What NVCR's price assumes
NovoCure Limited did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.51× revenue.
2.51
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 5.20
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 5.20
- EV / EBIToperating margin −22%: the multiple describes the denominator
- not meaningful
- Market capitalisation116.4 million shares, counted Jul 17, 2026
- $1.71B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.